Announces that it has successfully completed a multi-kilogram scale run under current good manufacturing practices of the active pharmaceutical ingredient of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd.. The cGMP material obtained from this study will be utilized in the Company's upcoming Phase 1 clinical study. MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. Marvel Biosciences Corp shares V.MRVL are trading unchanged at $0.12.